Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of his presentation, involving dosing of pembrolizumab in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer
Advertisement